

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CAL-62

RRID:CVCL_1112

Type: Cell Line

Proper Citation

RRID:CVCL_1112

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1112

Proper Citation: RRID:CVCL_1112

Description: Cell line CAL-62 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: [PMID:1369551](#), [PMID:18713817](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23833040](#), [PMID:25365311](#), [PMID:27397505](#), [PMID:30737244](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAL-62

Synonyms: Cal-62, CAL 62, Cal 62, CAL62, Centre Antoine Lacassagne-62

Cross References: BTO:BTO_0002146, CLO:CLO_0002187, EFO:EFO_0002126, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473548, BioSample:SAMN10988563, cancercellines:CVCL_1112, CCRID:3101HUMSCSP546, Cell_Model_Passport:SIDM00931, ChEMBL-Cells:ChEMBL3308099, ChEMBL-Targets:ChEMBL1075413, CLS:305114, Cosmic:891257, Cosmic:906828, Cosmic:1152118, Cosmic:1162838, Cosmic:1239974, Cosmic:2054116, Cosmic:2613252, Cosmic-CLP:906828, DepMap:ACH-000174, DSMZ:ACC-448, DSMZCellDive:ACC-448,

EGA:EGAS00001000978, GDSC:906828, GEO:GSM886911, GEO:GSM887977, GEO:GSM1669654, IARC_TP53:21213, IGRhCellID:CAL62, LiGeA:CCLE_550, LINCS_LDP:LCL-1683, PharmacDB:CAL62_174_2019, PRIDE:PXD030304, Progenetix:CVCL_1112, PubChem_Cell_line:CVCL_1112, Wikidata:Q54808410

ID: CVCL_1112

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260905T174513+0000

Ratings and Alerts

No rating or validation information has been found for CAL-62.

No alerts have been found for CAL-62.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lu B, et al. (2026) Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(13), e72118.

Feng N, et al. (2026) Unveiling ER-Phagy Receptors in Thyroid Cancer: A Combined Approach of Public Data Mining and In Vitro Validation. Clinical Medicine Insights. Oncology, 20, 11795549261460315.

Zhou R, et al. (2026) DNMT2 inhibits anaplastic thyroid cancer progression by downregulating 5'tiRNAGly-GCC production. Cell death & disease, 17(1).

Huo Y, et al. (2026) FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity. Cancer research, 86(9), 2184.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. Cell reports. Medicine, 6(10), 102411.

Grätz C, et al. (2025) Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer. Scientific reports, 15(1), 32464.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. *The Journal of clinical endocrinology and metabolism*, 110(4), 991.

Lim G, et al. (2025) AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. *iScience*, 28(8), 113194.

Martín-Vega A, et al. (2023) Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. *Science advances*, 9(7), eadd7969.

Bolf EL, et al. (2023) Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. *Cells*, 12(10).

Zhang Q, et al. (2021) Hsa_circ_0023990 Promotes Tumor Growth and Glycolysis in Dedifferentiated TC via Targeting miR-485-5p/FOXO1 Axis. *Endocrinology*, 162(12).

Montero-Conde C, et al. (2020) Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing. *International journal of cancer*, 146(2), 521.

Peplau E, et al. (2020) Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer. *Thyroid : official journal of the American Thyroid Association*, 30(9), 1314.

Marlow LA, et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. *The Journal of clinical endocrinology and metabolism*, 103(9), 3169.